Matches in Wikidata for { <http://www.wikidata.org/entity/Q64622130> ?p ?o ?g. }
Showing items 1 to 44 of
44
with 100 items per page.
- Q64622130 description "clinical trial" @default.
- Q64622130 description "ensayu clínicu" @default.
- Q64622130 description "klinisch onderzoek" @default.
- Q64622130 description "клінічне випробування" @default.
- Q64622130 name "Efficacy and Safety of Ranibizumab 0.5 vs Veteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia" @default.
- Q64622130 type Item @default.
- Q64622130 label "Efficacy and Safety of Ranibizumab 0.5 vs Veteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia" @default.
- Q64622130 prefLabel "Efficacy and Safety of Ranibizumab 0.5 vs Veteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia" @default.
- Q64622130 P1050 Q64622130-2BA51131-15D6-47AC-B579-BDA710050DE3 @default.
- Q64622130 P1132 Q64622130-E48C2929-9E4F-4070-B7E7-DE06B308AB94 @default.
- Q64622130 P131 Q64622130-635B2654-916F-4F39-B7E6-4299F2E21C13 @default.
- Q64622130 P1476 Q64622130-1286FBC9-C7FC-447D-8D44-60482650E98B @default.
- Q64622130 P17 Q64622130-12134783-89B0-43AA-A38B-2706A7D6405C @default.
- Q64622130 P17 Q64622130-5E9E68BF-9398-4239-B38E-E9489850C42D @default.
- Q64622130 P17 Q64622130-603ADDA5-2144-483E-982F-A63EE3BE6B91 @default.
- Q64622130 P1813 Q64622130-27B40579-67C1-4B61-83D6-8239FB13AA6F @default.
- Q64622130 P2899 Q64622130-FAA77420-1315-44E0-B10F-86DDC905B609 @default.
- Q64622130 P3098 Q64622130-ABCD6BF2-8311-473B-B084-9F7353F94E58 @default.
- Q64622130 P31 Q64622130-B6F2C043-ADAD-43B4-8992-9533EE505183 @default.
- Q64622130 P4844 Q64622130-CC0D1B64-3B1C-4025-86A3-F8790433340F @default.
- Q64622130 P580 Q64622130-71DC038C-BD40-4B41-AB44-7FF68E0AF399 @default.
- Q64622130 P582 Q64622130-3EFBA210-E65B-4446-AC73-CE8D5C672247 @default.
- Q64622130 P6099 Q64622130-84613FC2-1E55-4E0B-A6F7-0740EC198A81 @default.
- Q64622130 P6153 Q64622130-D87FD822-AD87-48F2-B4D1-5F1A384ED42A @default.
- Q64622130 P8363 Q64622130-E0ADC7CA-9235-458B-9AD5-C18643D431A2 @default.
- Q64622130 P859 Q64622130-83810138-8285-4F1D-8601-93726A55F3A8 @default.
- Q64622130 P1050 Q168403 @default.
- Q64622130 P1132 "+456" @default.
- Q64622130 P131 Q8646 @default.
- Q64622130 P1476 "A 12-month, Phase III, Randomized, Double-masked, Multicenter, Active-controlled Study to Evaluate the Efficacy and Safety of Two Individualized Regimens of 0.5mg Ranibizumab vs. Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia" @default.
- Q64622130 P17 Q668 @default.
- Q64622130 P17 Q869 @default.
- Q64622130 P17 Q928 @default.
- Q64622130 P1813 "Brilliance" @default.
- Q64622130 P2899 "+18" @default.
- Q64622130 P3098 "NCT01922102" @default.
- Q64622130 P31 Q30612 @default.
- Q64622130 P4844 Q414270 @default.
- Q64622130 P580 "2013-09-11T00:00:00Z" @default.
- Q64622130 P582 "2016-09-14T00:00:00Z" @default.
- Q64622130 P6099 Q42824827 @default.
- Q64622130 P6153 Q507154 @default.
- Q64622130 P8363 Q78089383 @default.
- Q64622130 P859 Q507154 @default.